Icecure Medical is trading 5.43% down now at $2.09, reversing from its $2.21 close on September 11, 2026, as the immediate catalyst remains unclear.
- The latest company-specific development was China’s September 10 NMPA approval for ProSense, allowing commercial marketing there.
- Available coverage does not directly explain September 14’s decline.
- Healthcare is outperforming, while broader markets are modestly lower.